A new microphysiological platform to study the permeation of neuroactive agents across intestinal and brain barriers
Open Access
- 25 March 2026
- journal article
- Published by IOP Publishing in Biofabrication
- Vol. 18 (2) , 025013
Abstract
To replicate key physiological barriers in vitro , we utilized the CELLBLOKS® modular microphysiological system. Specifically, human cerebral microvascular endothelial hCMEC/D3 cells, human retinal pigment epithelial cells, and rat small intestinal IEC-6 cells were grown in CELLBLOKS® to mimic the blood-brain (BBB), blood-cerebrospinal fluid (BCSFB), and intestinal (IB) barriers, respectively. Eugenol is an essential oil component known to permeate the central nervous system (CNS) in vivo after intravenous (IVA) and oral (OA) administrations; it was therefore used to simulate IVA and OA into the CELLBLOKS® system, using also celiprolol as negative control compound, since it is known for its poor ability to permeate in the CNS from the bloodstream. In particular, the IVA (systemic) of the compounds was simulated by their direct addition to the bloodstream-like lower channel of CELLBLOKS® (basolateral side of both BCSFB and IB; apical side for BBB), whereas their OA was simulated by apical addition to IEC-6. Permeation measurements, via High-performance liquid chromatography, across physiological barriers cultured in CELLBLOKS® demonstrated that, following both simulated oral and systemic administration, eugenol crosses the mimicked BBB and the BCSFB indiscriminately; conversely, the permeation of celiprolol across these barriers results strongly limited in comparison to eugenol. To assess downstream neuroactivity, dopaminergic neuron-like PC12 cells were cultured on NANOSTACKS™ inserts and incorporated into the BBB and BCSFB blocks. After simulated IVA and OA, significant eugenol-induced dopamine release by PC12 cells was evidenced both in BBB- and BCSFB-delimited neuronal-like compartments. These results validate the CELLBLOKS® and NANOSTACKS™ platforms as robust tools characterized by low costs, high reproducibility and ease of manipulation for in vitro studies of brain targeting of new drugs. This system requires two weeks culture period to be ready for the simulation in vitro of IB, BBB, BCFSB and neuronal tissues, appearing useful in limiting pre-clinical animal testing.Keywords
Funding Information
- Università degli Studi di Ferrara (2022-FAR.L-DA_018)
This publication has 52 references indexed in Scilit:
- Multicellular hepatic in vitro models using NANOSTACKSTM: human-relevant models for drug response predictionIn vitro models, 2025
- Mechanisms of cerebrospinal fluid secretion by the choroid plexus epithelium: Application to various intracranial pathologiesClinical Anatomy, 2024
- In vitro drug screening models derived from different PC12 cell lines for exploring Parkinson’s disease based on electrochemical signals of catecholamine neurotransmittersMicrochimica Acta, 2024
- Permeability‐Engineered Compartmentalization Enables In Vitro Reconstitution of Sustained Synthetic Biology SystemsAdvanced Science, 2022
- Unveiling the gut-brain axis: structural and functional analogies between the gut and the choroid plexus vascular and immune barriersSeminars in Immunopathology, 2022
- Introducing CELLBLOKS®: a novel organ-on-a-chip platform allowing a plug-and-play approach towards building organotypic modelsIn vitro models, 2022
- Involvement of influx and efflux transport systems in gastrointestinal absorption of celiprololJournal of Pharmaceutical Sciences, 2009
- Does monoamine oxidase inhibition by pargyline increase extracellular dopamine concentrations in the striatum?Neuroscience, 1996
- Effects of reuptake inhibitors on dopamine release from the stalk-median eminence and posterior pituitary in vitroBrain Research, 1991
- Comparative enantioselective pharmacokinetic studies of celiprolol in healthy volunteers and patients with impaired renal functionEuropean Journal of Clinical Pharmacology, 1990